Prana Biotechnology Limited (ADR)  

(Public, NASDAQ:PRAN)   Watch this stock  
Find more results for PRAN
-0.026 (-4.89%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.51 - 0.54
52 week 0.45 - 1.85
Open 0.54
Vol / Avg. 23,363.00/120,392.00
Mkt cap 28.52M
P/E     -
Div/yield     -
EPS -0.08
Shares 533.89M
Beta 0.52
Inst. own 0%
Feb 22, 2016
Interim 2016 Prana Biotechnology Ltd Earnings Release (Estimated) Add to calendar
Jan 29, 2016
Q2 2016 Prana Biotechnology Ltd KPI Quarterly Report - December 2015
Nov 12, 2015
Prana Biotechnology Ltd Annual Shareholders Meeting (Estimated)
Nov 12, 2015
Prana Biotechnology Ltd Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -5497.71% -3327.91%
Operating margin -10867.00% -9619.02%
EBITD margin - -9601.16%
Return on average assets -22.63% -14.10%
Return on average equity -24.44% -15.33%
Employees 15 -
CDP Score - -


L 2 369 Royal Pde, Parkville
+61-3-93494906 (Phone)
+61-3-93480377 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Prana Biotechnology Limited (Prana) is an Australia-based development stage medical biotechnology Company. The Company is engaged in commercializing research into Alzheimer's disease, Huntington disease and other major age-related degenerative disorders. The Company's lead drug candidate, PBT2 is being developed for the treatment of Alzheimer’s and Huntington's diseases. Prana Biotechnology is developing therapies to treat neurodegenerative disease. Prana Biotechnology also has advanced a drug candidate for Parkinson’s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. The Company's activities are predominantly within Australia and cover research into Alzheimer's disease and other major age-related degenerative disorders.

Officers and directors

Geoffrey Paul Kempler Executive Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
Kathryn Andrews Chief Financial Officer
Bio & Compensation  - Reuters
Dianne Angus Chief Operating Officer
Bio & Compensation  - Reuters
Phillip Hains Company Secretary
Bio & Compensation  - Reuters
Ira Shoulson Director
Bio & Compensation  - Reuters
Lawrence Gozlan Non-Executive Independent Director
Bio & Compensation  - Reuters
Peter Ashley Marks Non-Executive Independent Director
Bio & Compensation  - Reuters
Brian Derek Meltzer Non-Executive Independent Director
Bio & Compensation  - Reuters
George William Mihaly Non-Executive Independent Director
Bio & Compensation  - Reuters